Justin Taylor

AstraZeneca (United Kingdom) — United Kingdom

Medicine · Health Sciences

36h-index12.5kcitations271works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(97), Chronic Lymphocytic Leukemia Research(44), Nuclear Structure and Function(32), RNA Research and Splicing(30), Myeloproliferative Neoplasms: Diagnosis and Treatment(26)

Publications267 total

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program
Discover Oncology·2025Open Access
Therapeutic potential of STK17A targeted therapies
Bioorganic & Medicinal Chemistry Letters·2025
Supplementary Methods from Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
2025Open Access
Supplementary Tables from Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
2025Open Access
Supplementary Figures S1-S8 from Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
2025Open Access
Big cells, bigger BTK resistance in mantle cell lymphoma
Blood·2025Open Access
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
Blood·2025Open Access
Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series
Blood·2025Open Access
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes
Blood·2025
Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts
Blood·2025Open Access
CNSC-31. TARGETING STK17A IN GLIOBLASTOMA: A NOVEL THERAPEUTIC STRATEGY USING BRAIN-PENETRANT INHIBITORS
Neuro-Oncology·2025Open Access
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
2025Open Access
Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy
Genes·2025Open Access
ChatGPT’s role in the rapidly evolving hematologic cancer landscape
Future Science OA·2025Open Access
Supplementary Table S2 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
2025Open Access
Supplementary Figure S6 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
2025Open Access
Supplementary Table S1 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
2025Open Access
Supplementary Table S3 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
2025Open Access
Supplementary Figure S7 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
2025Open Access
Supplementary Figure S1 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
2025Open Access
page 1 of 14Next →

Frequent Co-authors

Omar Abdel‐Wahab(28), Martin S. Tallman(10), Akihide Yoshimi(8), Stanley Chun-Wei Lee(8), Eric Padron(7), Benjamin H. Durham(7), Sydney X. Lu(7), Andrew M. Brunner(7), Mrinal M. Patnaik(7), Jan Philipp Bewersdorf(7), Virginia M. Klimek(6), Daichi Inoue(6), Mikkael A. Sekeres(6), Rami S. Komrokji(6), Hetty E. Carraway(6), Maximilian Stahl(6), Silvia Buonamici(5), Young Rock Chung(5), Robert K. Bradley(5), Mikhail Roshal(5)